Table 1 Baseline characteristics of the study population
Characteristic | Pembrolizumab plus chemotherapy, N = 351 | Pembrolizumab monotherapy, N = 571 | p-value2 |
|---|---|---|---|
Primary tumor location | 0.2 | ||
Larynx | 10 (29%) | 12 (21%) | |
Oral cavity | 17 (49%) | 36 (63%) | |
Oropharynx | 8 (23%) | 6 (11%) | |
Other/unspecified | 0 (0%) | 3 (5.3%) | |
Age | < 0.001 | ||
< 65 | 21 (60%) | 7 (12%) | |
65–75 | 8 (23%) | 18 (32%) | |
> 75 | 6 (17%) | 32 (56%) | |
Sex | > 0.9 | ||
Female | 12 (34%) | 20 (35%) | |
Male | 23 (66%) | 37 (65%) | |
ECOG PS | < 0.001 | ||
0 | 21 (60%) | 18 (32%) | |
1 | 14 (40%) | 16 (28%) | |
2 | 0 (0%) | 23 (40%) | |
PD-L1 CPS | > 0.9 | ||
PD-L1 CPS 1–19 | 14 (40%) | 23 (40%) | |
PD-L1 CPS > = 20 | 21 (60%) | 34 (60%) | |
Smoke | 0.2 | ||
Current smoker | 20 (57%) | 22 (39%) | |
Never smoker | 8 (23%) | 18 (32%) | |
Previous smoker | 7 (20%) | 17 (30%) | |
Previous radiochemotherapy | 0.016 | ||
No radiochemotherapy | 32 (91%) | 40 (70%) | |
Previous radiochemotherapy | 3 (8.6%) | 17 (30%) | |
Tumor burden | 0.2 | ||
<=2 sites | 22 (63%) | 28 (49%) | |
> 2 sites | 13 (37%) | 29 (51%) | |
HPV | 0.2 | ||
Negative/unknown | 31 (89%) | 55 (96%) | |
Positive | 4 (11%) | 2 (3.5%) | |
Platinum agent | > 0.9 | ||
Carboplatin | 10 (29%) | 0 (NA%) | |
Cisplatin | 25 (71%) | 0 (NA%) | |
Unknown | 0 | 57 |